ClinicalTrials.gg
RecruitingNCT06484530Updated Jul 3, 2024

Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis

A Phase 4 interventional study of N acetyl cysteine in Tuberculosis (TB), Isoniazid Toxicity and Rifampicin Toxicity, sponsored by Mahidol University. Recruiting at 1 site in Thailand. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Mahidol University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Tuberculosis with a site in Thailand — 5 open to participants now, 8 under way, 1 of them phase 3. Tuberculosis · Thailand.

Planned enrollment
17th of 30
116 · median 130
Started
2024
with 3 others
Phase 4
5 of 36
1 open now
Registered
32nd of 36
by date
Lead sponsor
4 of 36
Mahidol University

Among the 36 studies in Tuberculosis with a site in Thailand, this one is the 17th largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2024, is one of 5 in phase 4, and was the 32nd registered.

Tuberculosis

1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

5 of the 36 studies in Tuberculosis with a site in Thailand are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Tuberculosis with a site in Thailand, or all of them as a file.
02

Study summary

Tuberculosis (TB) remains a significant public health concern in Thailand and globally, especially in tropical regions, with pulmonary TB being predominant. Besides affecting the lungs, TB can also impact extrapulmonary organs. Standard TB treatment involves a combination of drugs administered for at least 6 months, but it can cause adverse effects such as hepatitis. Hepatotoxicity, occurring in 20-60% of patients, is commonly linked to isoniazid, rifampicin, and pyrazinamide. Slow acetylators of the NAT2 gene are particularly susceptible. Previous research suggests N-acetylcysteine (NAC) may mitigate hepatotoxicity, especially among slow acetylators. A recent study by Kittichai Samaithongcharoen and team showed that NAC reduced hepatotoxicity incidence significantly among slow acetylators. This underscores the potential of NAC in preventing drug-induced hepatotoxicity in TB treatment, warranting further investigation against standard treatment protocols.

Read the detailed description

Tuberculosis (TB) is a significant public health problem in Thailand and globally, especially in hot climates. TB infection is commonly found in the lungs, but it can also affect other important organs such as lymph nodes, pleura, abdomen, musculoskeletal system, urinary tract, and nervous system. The current standard treatment regimen for TB consists of a combination of drugs (isoniazid, rifampicin, pyrazinamide, and ethambutol), used for new TB patients who have not been treated before or have received less than 1 month of treatment. A major challenge in TB treatment is that patients must take multiple drugs continuously for at least 6 months, with common side effects including skin rash, dizziness, hepatitis, nausea, vomiting, and abdominal pain, often occurring within the first 2 months of treatment. Hepatotoxicity from anti-TB drugs is a common side effect, occurring in 20-60% of patients, mostly within the first 2 weeks to 2 months of starting treatment. Isoniazid, rifampicin, and pyrazinamide are the drugs most commonly associated with hepatotoxicity, typically causing hepatocellular injury of varying severity. NAT2 slow acetylator phenotype individuals are at higher risk. Studies in Thailand have found a high prevalence (25-30%) of NAT2 slow acetylators among Thai people. Preventing hepatotoxicity from anti-TB drugs is crucial, especially for high-risk patients, although clear guidelines are lacking. Previous studies have shown that administering N-acetylcysteine (NAC), an antioxidant, can reduce hepatotoxicity, particularly in slow acetylators. A recent controlled study by Kittichai Samaithongcharoen and colleagues demonstrated the significant efficacy of NAC in preventing hepatotoxicity in slow acetylators receiving standard TB treatment, with no cases of hepatotoxicity compared to a 50% incidence in the control group. Further research is needed to explore the effectiveness of NAC administration for preventing hepatotoxicity from anti-TB drugs, based on NAT2 genotype testing, compared to current standard TB treatment protocols.

03

Conditions studied

  • Tuberculosis (TB)
  • Isoniazid Toxicity
  • Rifampicin Toxicity
  • Pyrazinamide Adverse Reaction
  • Ethambutol Toxicity
  • NAT2 Slow Acetylator Status
  • NAT2 Rapid Acetylator Status
  • NAT2 Polymorphism
  • N-Acetylcysteine

Browse trials for

Keywords

  • Tuberculosis (TB)
  • Isoniazid Toxicity
  • Rifampicin Toxicity
  • Pyrazinamide Adverse Reaction
  • Ethambutol Toxicity
  • NAT2 Slow Acetylator Status
  • NAT2 Rapid Acetylator Status
  • NAT2 Polymorphism
  • N-Acetylcysteine
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 - 80 years old.
  • Newly diagnosed tuberculosis patients (both pulmonary and extrapulmonary).
  • Received standard anti-tuberculosis medication according to standard regimens (2HRZE/4HR, 2HRE/7HR).
  • Willing to participate in the research

Exclusion criteria

Exclusion Criteria:

  • Infected with .
  • Severe liver dysfunction classified as B or C.
  • Chronic untreated liver diseases such as or C, alcoholic liver disease.
  • Abnormal liver function tests including > 1.5 times the (48 U/L), ALT > 1.5 times the upper limit of normal (55 U/L), ALP > upper limit of normal (110 U/L), Total > upper limit of normal (1.2 mg/dL).
  • Diagnosed with cancer.
  • History of allergy to N-acetylcysteine (NAC).
  • Pregnant or breastfeeding.
  • Severe comorbidities such as CKD stage 4-5, chronic heart failure, severe pulmonary diseases (, bronchiectasis).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    NAT2 gene testing group

    Tuberculosis patients will undergo NAT2 gene testing before starting anti-tuberculosis medication. If the NAT2 gene phenotype is identified as slow acetylator, the patient will receive NAC medication at a dose of 600 mg twice daily for 8 weeks in addition to anti-tuberculosis medication. If the NAT2 gene phenotype is identified as rapid or intermediate acetylator, the patient will receive only anti-tuberculosis medication.

    Drug: N acetyl cysteine

  • No intervention
    Non NAT2 gene testing

    Tuberculosis patients will receive standard anti-tuberculosis medication without NAT2 gene testing.

Interventions

  • DrugAcetylcysteineStudies of AcetylcysteineAcetylcysteine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1,200 mg/day for 8 weeks in NAT2 gene testing group and NAT2 gene phenotype is identified as slow acetylator.

    Also known as: Standard anti TB drug regimen

06

What researchers measure

Primary outcomes

  1. Prevalence of hepatitis at 8 weeks

    To study the efficacy of administering N-acetylcysteine (NAC) to prevent drug-induced hepatitis at 8 weeks from anti-tuberculosis medication using gene-guided therapy compared to conventional therapy. Significant hepatitis was defined as elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than 5 times of baseline levels or Total bilirubin(TB) more than 2.5 milligrams per decilitre (mg/dL)

    Time frame: 8 weeks

Secondary outcomes

  1. Prevalence of hepatitis at 2 weeks

    To study the efficacy of administering N-acetylcysteine (NAC) to prevent drug-induced hepatitis at 2 weeks from anti-tuberculosis medication using gene-guided therapy compared to conventional therapy. Significant hepatitis was defined as elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than 5 times of baseline levels or Total bilirubin(TB) more than 2.5 milligrams per decilitre (mg/dL)

    Time frame: 2 weeks

Other outcomes

  1. Prevalence of hepatitis at 24 weeks

    To study the efficacy of administering N-acetylcysteine (NAC) to prevent drug-induced hepatitis at 24 weeks from anti-tuberculosis medication using gene-guided therapy compared to conventional therapy. Significant hepatitis was defined as elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than 5 times of baseline levels or Total bilirubin(TB) more than 2.5 milligrams per decilitre (mg/dL)

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
  • Faculty of Medicine Siriraj Hospital, Mahidol University
    Bangkok Noi, Bangkok 10700, Thailand
    Recruiting
    • Pongpot Namasae, MD · Contactshy.pongpot@gmail.com · +66954408520
    • Supot Nimanong, MD · Contactsupotgi@gmail.com · +66819134336
    • Pongpot Namasae, MD · Sub investigator
    • Supot Nimanong, MD · Principal investigator
08

References and documents

Publications

  • Palwatwichai A. Tuberculosis in Thailand. Respirology. 2001 Mar;6(1):65-70. doi: 10.1046/j.1440-1843.2001.00299.x. PubMed 11264766 ↗
  • Treatment of Tuberculosis: Guidelines. 4th edition. Geneva: World Health Organization; 2010. Available from http://www.ncbi.nlm.nih.gov/books/NBK138748/ PubMed 23741786 ↗
  • Wiwatworapan T, Anantasetagoon T. Extra-pulmonary tuberculosis at a regional hospital in Thailand. Southeast Asian J Trop Med Public Health. 2008 May;39(3):521-5. PubMed 18564694 ↗
  • Bouazzi OE, Hammi S, Bourkadi JE, Tebaa A, Tanani DS, Soulaymani-Bencheikh R, Badrane N, Bengueddour R. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors. Pan Afr Med J. 2016 Nov 16;25:167. doi: 10.11604/pamj.2016.25.167.10060. eCollection 2016. PubMed 28292129 ↗
  • Anand AC, Seth AK, Paul M, Puri P. Risk Factors of Hepatotoxicity During Anti-tuberculosis Treatment. Med J Armed Forces India. 2006 Jan;62(1):45-9. doi: 10.1016/S0377-1237(06)80155-3. Epub 2011 Jul 21. PubMed 27407844 ↗
  • Gaude GS, Chaudhury A, Hattiholi J. Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients. J Family Med Prim Care. 2015 Apr-Jun;4(2):238-43. doi: 10.4103/2249-4863.154661. PubMed 25949974 ↗
  • Ramappa V, Aithal GP. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. J Clin Exp Hepatol. 2013 Mar;3(1):37-49. doi: 10.1016/j.jceh.2012.12.001. Epub 2012 Dec 20. PubMed 25755470 ↗
  • Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002 Dec 17;137(12):947-54. doi: 10.7326/0003-4819-137-12-200212170-00007. PubMed 12484709 ↗
  • Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest. 2005 Jul;128(1):116-23. doi: 10.1378/chest.128.1.116. PubMed 16002924 ↗
  • Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis. 1978 Jun;117(6):991-1001. doi: 10.1164/arrd.1978.117.6.991. PubMed 666111 ↗
  • International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982;60(4):555-64. PubMed 6754120 ↗
  • Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 1991 Feb;99(2):465-71. doi: 10.1378/chest.99.2.465. No abstract available. PubMed 1824929 ↗
  • Thongraung W, Sittidach M, Khwansuwan P, Sariyasuntorn K, Wongsampan S. Evaluation of the physicians' approach to the diagnosis and treatment of patients with antituberculosis drug-induced hepatotoxicity. J Eval Clin Pract. 2012 Dec;18(6):1119-25. doi: 10.1111/j.1365-2753.2011.01706.x. Epub 2011 Jun 22. PubMed 21696520 ↗
  • Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002 Apr;35(4):883-9. doi: 10.1053/jhep.2002.32102. PubMed 11915035 ↗
  • Yang S, Hwang SJ, Park JY, Chung EK, Lee JI. Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis. BMJ Open. 2019 Aug 1;9(8):e027940. doi: 10.1136/bmjopen-2018-027940. PubMed 31375612 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Sep 2024, 6 months after the start.

Of 22 phase 4 interventional studies under Tuberculosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 47. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2024
First posted
Jul 3, 2024
StartActual
Mar 12, 2024
Primary completionEst.
Sep 18, 2024
CompletionEst.
Sep 18, 2024
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06484530
Lead sponsor
Mahidol University
Responsible party
Watcharasak Chotiyaputta (Associate professor, Faculty of Medicine, Siriraj, Mahidol University) — Principal investigator
First posted
Jul 3, 2024
Start date
Mar 12, 2024
Primary completion
Sep 18, 2024 (estimated)
Completion
Sep 18, 2024 (estimated)
Last update
Jul 3, 2024

Study contacts

Pongpot Namasae
Contact
shy.pongpot@gmail.com
66954408520
Supot Nimanong
Contact
supotgi@gmail.com
66819134336
Supot Nimanong
principal investigator · Mahidol University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetylcysteine

Start the discussion